OBJECTIVE To follow the change in streptokinase neutralisation titres in a group of patients after treatment with streptokinase for acute myocardial infarction. DESIGN Venous blood samples suitable for analysis were obtained up to 866 days after treatment with 1.5 million units of streptokinase in 189 patients. The ability of the patient's plasma to inhibit lysis of a thrombin clot by strepto...

A comparison was made of the esterase and activator activities of the various activated forms of human plasminogen and their streptokinase complexes with Nalpha-Cbz-L-lysine-p-nitrophenyl ester as the substrate. The steady state kinetic properties of Glu- and Lys-plasmins, and Glu- and Lys-plasminogen-streptokinase complexes were identical, while the Lys-plasmin-streptokinase complex showed a 2...

background: streptokinase is a potent activator of plasminogen to plasmin, the enzyme that can solubilize the fibrin network in blood clots. streptokinase is currently used in clinical medicine as a thrombolytic agent. it is naturally secreted by β-hemolytic streptococci. methods: to reach an efficient method of purification, an immunoaffinity chromatography method was developed that could puri...

T HE FEASIBILITY of producing dissolution of thrombi by enzymatic means has been demonstrated in experimental thrombi and pulmonary emboli in animals, in experimental venous thrombi in man6 and in patients with acute venous and arterial thromboembolic disease.7 8 Of the enzymes investigated, only the two plasminogen activators, streptokinase and urokinase, have proved acceptable as thrombolytic...

STUDY OBJECTIVE To investigate the effects of streptokinase and deoxyribonuclease (DNase) on the viscosity of pus to assess whether the DNase in the old preparation of streptokinase-streptodornase used intrapleurally to treat empyema was contributing to easier drainage of pus compared with purified streptokinase. DESIGN In vitro measurement of pus viscosity. PATIENTS Pus from three patients...

BACKGROUND AND OBJECTIVES Streptokinase is used clinically as an intravenous thrombolytic agent for the treatment of acute myocardial infarction and is commonly prepared from cultures of Streptococcus equisimilis strain H46A. The objective of the present study was the production of streptokinase from strain H46A and purification by chemical reduction method. MATERIALS AND METHODS The rate of ...

When streptokinase is incubated with human or rabbit plasminogen, one event which occurs is a specific fragmentation of streptokinase. At least five major identifiable streptokinase fragments appear with time, and they possess molecular weights of approximately 40,000 (SK I), 36,000 (SK 2), 31,000 (SK 3), 26,000 (SK 4), and 10,000 (SK 5) under denaturing conditions, as observed on calibrated so...

BACKGROUND A major limitation of streptokinase is the development and persistence of problematic neutralizing antibodies that have the potential to limit the effectiveness of repeat streptokinase therapy. Accordingly, tissue-type plasminogen activator (t-PA) is frequently administered to patients with recurrent infarction presenting more than four days from previous treatment with streptokinase...

the measurement of anti-streptokinase antibodies can distinguish the patients who may benefit from streptokinase and those who should be treated with some other thrombolytic regimen. neutralising titration test is a commonly used classical assay for measuring anti-streptokinase antibodies and in this assay the ability of anti-streptokinase antibodies in patients' sera in preventing the lytic ef...

Streptokinase is shown to react with either human plasmin or human plasminogen to form an equimolar product which migrates in starch gel electrophoresis at pH 6.0 or 8.0 with a migration rate intermediate between the rates of migration of the two proteins. When streptokinase was present in molar excess in the reaction mixtures, the uncombined streptokinase displayed a migration rate at pH 6.0 (...